MedTrace Logo

Study of AT-527 in Subjects With Normal and Impaired Renal Function

NCT05618314 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-07-31

No results posted yet for this study

Summary

Study of AT-527 in Subjects with Normal and Impaired Renal Function

Conditions

  • Healthy Volunteer
  • Renal Impairment

Interventions

DRUG

AT-527

single dose AT-527

DRUG

AT-527

Single dose of AT-527 pre- and post-dialysis

DRUG

AT-527 and Probenecid

Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19

Sponsors & Collaborators

  • Atea Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2024-06-15
Completion
2024-06-15
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618314 on ClinicalTrials.gov